www.sec.gov/Archives/edgar/data/880643/.../genta_8k-011812.htm
On January 18, 2012, the Company entered into an amendment agreement (the “Twelfth Amendment Agreement”) with certain investors in the September 2011 Financing to amend the terms of the September 2011 Purchase Agreement to extend the deadline for the Company to effect a reverse stock split. As a result of the Twelfth Amendment Agreement, absent any further waiver or amendment, the reverse split must be implemented by February 15, 2012. The Company sought this amendment to the September 2011 Purchase Agreement to enable the continuation of ongoing discussions regarding corporate partnership opportunities for tesetaxel.